Updated Jul 16, 2026
Bhalla Narinder Pal has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $99K.
Narinder Pal Bhalla is associated with Lexeo Therapeutics, Inc., a company focused on developing therapies for genetic diseases. Specific details about his role or contributions are not widely documented.
| Role | Insider |
|---|---|
| Notability | 10/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-01 | LXEO | Lexeo Therapeutics, Inc. | S — Open-market sale | 22.3K | $4.42 | $99K |
| 2026-07-01 | LXEO | Lexeo Therapeutics, Inc. | A — Grant or award | 55.0K | $0.00 | |
| 2026-02-17 | LXEO | Lexeo Therapeutics, Inc. | A — Grant or award | 49.5K | $0.00 |
Narinder Pal Bhalla is associated with Lexeo Therapeutics, Inc., a company focused on developing therapies for genetic diseases. Specific details about his role or contributions are not widely documented.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($99K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Bhalla Narinder Pal profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.